The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer.

ABSTRACT: Despite advances in treatment strategies and surgical approaches in recent years, improving survival outcomes in esophagogastric cancer (EGC) patients treated with curative intent remains a significant area of unmet need. The recent emergence of adjuvant immunotherapy as the standard of care for resected EGC demonstrates the impact of immunotherapy in improving recurrence-free survival. Neoadjuvant and perioperative immunotherapies represent another promising approach with potential advantages over adjuvant therapy. Despite the promising results of early neoadjuvant immunotherapy studies, there are several challenges and future research needs. The optimal timing, duration and number of doses in relation to surgery and the optimal combination of immunotherapies are still unclear. In additio

SUBMITTER: Dennehy C 

PROVIDER: S-EPMC10814157 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature